SLC22A1 and cancer: Because inhibition of OCT1/2 could decrease the uptake of metformin in the liver and its elimination in the kidney, and might reduce its hepatic anti-hyperglycemic action, there is a possible undesirable interaction between rucaparib and metformin in diabetic cancer patients who are treated by these two drugs.